Pathology Diagnostics Ltd, St John's Innovation Centre, Cowley Road, Cambridge, CB4 0WS, UK.
Biomark Med. 2011 Apr;5(2):227-48. doi: 10.2217/bmm.11.9.
There has been increased interest in the analysis of protein biomarkers in clinical tumor tissues in recent years. Tissue-based biomarker assays can add value and aid decision-making at all stages of drug development, as well as being developed for use as predictive biomarkers and for patient stratification and prognostication in the clinic. However, there must be an awareness of the legal and ethical issues related to the sourcing of human tissue samples. This article also discusses the limits of scope and critical aspects on the successful use of the following tissue-based methods: immunohistochemistry, tissue microarrays and automated image analysis. Future advances in standardization of tissue biobanking methods, immunohistochemistry and quantitative image analysis techniques are also discussed.
近年来，人们对分析临床肿瘤组织中的蛋白质生物标志物越来越感兴趣。基于组织的生物标志物检测可以在药物开发的各个阶段增加价值并辅助决策，并且还可以作为预测生物标志物以及在临床中进行患者分层和预后预测而开发。但是，必须意识到与人类组织样本来源相关的法律和道德问题。本文还讨论了以下基于组织的方法的成功使用的范围限制和关键方面：免疫组织化学、组织微阵列和自动图像分析。还讨论了组织生物库方法、免疫组织化学和定量图像分析技术的标准化的未来进展。
